Communiqués Phathom Pharmaceuticals, Inc.

Actions

PHAT

US71722W1071

Produits pharmaceutiques

Temps réel estimé Cboe BZX 16:16:58 05/10/2026			Varia. 5j.	Varia. 1 janv.
6,865 ^USD	-0,79%		-5,44%	-58,11%

29/09	Phathom Pharmaceuticals, Inc. lance une étude pivot de phase 3 de VOQUEZNA pour le traitement à la demande du reflux gastro-œsophagien non érosif	CI
29/09	Phathom Pharmaceuticals lance une étude pivotale de phase 3 sur Voquezna	MT

Communiqués

29/09	Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD	GL
01/09	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
30/07	Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
20/07	Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026	GL
23/06	Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)	GL
22/05	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
20/05	Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting	GL
04/05	Phathom Pharmaceuticals to Highlight VOQUEZNA at DDW 2026 Annual Meeting	AQ
01/05	Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting	GL
30/04	Phathom Pharmaceuticals : First Quarter 2026 Earnings Call Presentation – April 2026	PU
30/04	Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	GL
20/04	Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026	GL
06/04	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
26/02	Phathom Pharmaceuticals : Fourth Quarter 2025 Earnings Call Presentation – February 2026	PU
26/02	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance	GL
23/02	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences	GL
17/02	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026	GL
05/02	Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026	GL
08/01	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants	GL
08/01	Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants	AQ
07/01	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	GL
07/01	Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results	GL
05/11	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA in Eosinophilic Esophagitis	AQ
04/11	Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)	GL
03/11	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences	GL